Replimune Group, Inc. (NASDAQ:REPL), a biotechnology firm specializing in biological products, disclosed a stock sale by Chief Commercial Officer Christopher Sarchi. On May 16, 2024, Sarchi sold 2,218 shares of Replimune stock, totaling approximately $14,350.
The transactions were executed at a weighted average price between $6.46 and $6.55 per share, according to the filing. The sale was part of a pre-arranged plan to cover tax withholding obligations related to the partial vesting of Sarchi's Restricted Stock Units (RSUs). It is noted that the sale does not represent a discretionary trading decision by the executive.
Following the sale, Sarchi directly owns 92,252 shares of Replimune Group, Inc. The company, headquartered in Woburn, Massachusetts, remains a key player in the biotech industry, with its stock traded under the ticker symbol REPL.
Investors and security holders may request detailed information about the exact prices at which the stock was sold within the reported range. The sale was reported in a Form 4 filing with the Securities and Exchange Commission, dated May 20, 2024.
InvestingPro Insights
Replimune Group, Inc. (NASDAQ:REPL) has experienced significant financial and market performance fluctuations, as indicated by real-time data from InvestingPro. With a market capitalization of $364.81 million, the company is navigating a challenging landscape. The stock has been trading near its 52-week low, with the price at the previous close standing at $6.44. This level is only 23.94% of its 52-week high, reflecting a notable decline in investor confidence.
InvestingPro Tips suggest that Replimune is quickly burning through cash and has not been profitable over the last twelve months. This is corroborated by a negative P/E ratio of -1.81 and an operating income of -$232.85 million for the same period. The company's financial health is further highlighted by a 1-year price total return of -69.66%, underscoring the stock's downward trajectory over the past year.
Despite these challenges, Replimune holds more cash than debt on its balance sheet, which could provide some cushion against short-term financial pressures. Additionally, the company's liquid assets exceed short-term obligations, offering a degree of financial stability. Investors looking to delve deeper into Replimune's financials and stock performance can find additional InvestingPro Tips on the company's profile at https://www.investing.com/pro/REPL. There are currently 5 more tips available, which could provide further insights into the company's outlook.
To gain comprehensive access to these insights, readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, enhancing their investment decision-making with valuable data and expert analysis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.